2014 CME Symposia - Dinner Symposium A
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
Dinner Symposium A
Thursday · 7:00 - 9:00pm
The Wide Spectrum of Familial Hypercholesterolemia: Discovering Your Highest Risk Patients and Optimizing Treatment
Supported by educational grants from Aegerion Pharmaceuticals, Inc. and Genzyme, A SANOFI COMPANY | Endorsed by The FH Foundation
Worldwide, there are at least 20 million people with familial hypercholesterolemia (FH). Despite the availability of effective treatment options and the prevalence of the disease, FH is both underdiagnosed and undertreated. This symposium will address knowledge and practice gaps in the identification and management of patients with severe FH. The faculty will provide expert recommendations for diagnosing FH and cascade family screening, and will present the most current evidence on novel therapeutic options. Patient Advocates from The FH Foundation will share their personal experiences with this life-threatening disease and efforts to improve awareness and encourage proactive treatment.
- Review the prevalence and associated cardiovascular risk of familial hypercholesterolemia (FH) in order to increase awareness and understanding of the disease.
- Describe the pathophysiology of familial hypercholesterolemia and list genetic variants that cause an increase in LDL-C levels and therefore cardiovascular risk.
- Explain how to implement screening strategies in pediatric and adult patients for prompt diagnosis of FH and early treatment.
- Describe current guidelines in clinical practice for screening, diagnosis, and management of individuals with FH.
- Review novel pharmacologic treatment options as well as LDL apheresis to overcome limitations of current treatment options and to determine management plans to optimize outcomes.
- Provide strategies for overcoming provider-patient barriers in communication to help individuals with FH recognize and appreciate their level of risk, the importance of family screening and the need to adhere to therapy.
Preliminary Agenda & Faculty
|7:00 - 7:15pm
||Familial Hypercholesterolemia: The Evolution of a Disease over the Last 40 Years
||Chairperson: Seth J. Baum, MD
|7:15 - 7:40pm
||Strategies for Early Identification, Diagnosis, and Cascade Screening
||Presenter: Sarah de Ferranti, MD, MPH
|7:40 - 8:20pm
||Advanced Approaches for Optimizing Outcomes in the Severe FH Patient
||Presenters: Patrick Moriarty, MD and Pamela Morris, MD
|8:20 - 8:35pm
||The Faces of Familial Hypercholesterolemia: A Call to Action from the FH Community
||Presenters: Catherine Davis Ahmed and Scott Radabaugh
|8:35 - 9:00pm
||Key Take-Home Messages, Panel Discussion and Audience Q&A
||Moderator: Seth J. Baum, MD
Presenters: Catherine Davis Ahmed; Sarah de Ferranti, MD, MPH; Patrick Moriarty, MD; Pamela Morris, MD; Scott Radabaugh
Seth J. Baum, MD
- Medical Director, Women's Preventive Cardiology
- Christine E. Lynn Women's Health & Wellness Institute
- Boca Raton Regional Hospital
- Voluntary Associate Professor of Medicine
- Miller School of Medicine
- University of Miami
- Boca Raton, FL
Sarah de Ferranti, MD, MPH
- Director, Preventive Cardiology Program
- Assistant Professor of Pediatrics
- Harvard Medical School
Patrick M. Moriarty, MD
- Director, Atherosclerosis/LDL-Apheresis Center
- Professor of Medicine
- University of Kansas Medical Center
- Kansas City, KS
Pamela B. Morris, MD
Director, Seinsheimer Cardiovascular Health Program
Co-Director, Women's Heart Care
Medical University of South Carolina
- FH Advocate
- The FH Foundation
Catherine David Ahmed, MD
- FH Advocate and Director of Outreach
- The FH Foundation
View Complete Accreditation Details and Program Overview: CMHC Accreditation